SEC Form 4 · accession 0001140361-17-018661
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sophie V. Vandebroek
Director
Period of report
May 3, 2017
Accepted (ET)
May 5, 2017 · 6:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Stock UnitF3,F1 | — | May 3, 2017 | A | 289 | A | — | — | Common Stock | 289 | 2,720 | D |
| Non-Qualified Stock Option (right-to-buy)F3,F2 | $160.28 | May 3, 2017 | A | 3,046 | A | — | May 2, 2027 | Common Stock | 3,046 | 3,046 | D |
Explanation of responses
- F1Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of stockholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.
- F2Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on May 3, 2018.
- F3Not applicable.